HALOZYME THERAPEUTICS, INC. Accumulated Other Comprehensive Income
HALOZYME THERAPEUTICS, INC. (HALO) had Accumulated Other Comprehensive Income of -$7.83 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$7.83M.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$12.70M.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$18.09M.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$22.26M.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-30 | -$7.83M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | -$12.70M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | -$18.09M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | -$22.26M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | -$28.40M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | -$3.41M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $3.83M 10-K · filed 2026-02-17 | |
| 2024-09-30 | -$6.94M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | -$2.07M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | -$1.49M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | -$9.28M 10-K · filed 2025-02-18 | |
| 2023-09-30 | $1.23M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | -$1.61M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $24.00K 10-Q · filed 2023-05-09 | |
| 2022-12-31 | -$922.00K 10-K · filed 2024-02-20 | |
| 2022-09-30 | -$1.84M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | -$2.02M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | -$2.79M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | -$620.00K 10-K · filed 2023-02-21 | |
| 2021-09-30 | -$14.00K 10-Q · filed 2021-11-02 | |
| 2021-06-30 | -$24.00K 10-Q · filed 2021-08-09 | |
| 2021-03-31 | -$9.00K 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $22.00K 10-K · filed 2022-02-22 | |
| 2020-09-30 | $426.00K 10-Q · filed 2020-11-02 | |
| 2020-06-30 | $1.09M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $11.00K 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $240.00K 10-K · filed 2021-02-23 | |
| 2019-09-30 | $392.00K 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $390.00K 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $61.00K 10-Q · filed 2019-05-07 | |
| 2018-12-31 | -$277.00K 10-K · filed 2020-02-24 | |
| 2018-09-30 | -$478.00K 10-Q · filed 2018-11-06 | |
| 2018-06-30 | -$736.00K 10-Q · filed 2018-08-07 | |
| 2018-03-31 | -$870.00K 10-Q · filed 2018-05-10 | |
| 2017-12-31 | -$450.00K 10-K · filed 2019-02-21 | |
| 2017-09-30 | -$53.00K 10-Q · filed 2017-11-07 | |
| 2017-06-30 | -$61.00K 10-Q · filed 2017-08-08 | |
| 2017-03-31 | -$49.00K 10-Q · filed 2017-05-09 | |
| 2016-12-31 | -$6.00K 10-K · filed 2018-02-20 | |
| 2016-09-30 | $83.00K 10-Q · filed 2016-11-07 | |
| 2016-06-30 | $216.00K 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $88.00K 10-Q · filed 2016-05-09 | |
| 2015-12-31 | -$99.00K 10-K · filed 2017-02-28 | |
| 2015-09-30 | $0.00 10-Q · filed 2015-11-09 | |
| 2015-06-30 | -$40.00K 10-Q · filed 2015-08-10 | |
| 2015-03-31 | -$27.00K 10-Q · filed 2015-05-11 | |
| 2014-12-31 | -$41.00K 10-K · filed 2016-02-29 | |
| 2014-09-30 | -$46.00K 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $3.00K 10-Q · filed 2014-08-11 | |
| 2014-03-31 | -$25.00K 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $17.00K 10-K · filed 2015-03-02 | $17.05K 10-K · filed 2014-02-28 |
| 2013-09-30 | $15.78K 10-Q · filed 2013-11-08 | |
| 2013-06-30 | -$39.31K 10-Q · filed 2013-08-07 | |
| 2013-03-31 | -$29.13K 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $0.00 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |